Ciclosporin ophthalmic - Santen
Alternative Names: Cyclosporin modified ophthalmic - Santen; Cyclosporin ophthalmic - Santen; DE 076; PAPILOCK Mini ophthalmic solution 0.1%; SancicloLatest Information Update: 02 Oct 2021
At a glance
- Originator Novartis
- Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
- Mechanism of Action Cytokine inhibitors; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Seasonal allergic rhinitis
Most Recent Events
- 23 Jan 2006 First global launch of ciclosporin ophthalmic
- 23 Jan 2006 Launched for Seasonal allergic rhinitis in Japan (Ophthalmic)
- 11 Oct 2005 Registered for Seasonal allergic rhinitis in Japan (Ophthalmic)